Marc Vincent Barcelona, MD, FPCR, DPBR-RO

#RadOnc Fellow @RadMedPM, hubby of #Peds #HemOnc, clinical cancer research, interests in #hncsm #pcsm #bcsm #kcsm #oligomets #MRgRT #IGBT #SBRT

[Hathal Haddad @Radiooncology]

🔰 New Series: Awareness of #Interventional_Radiotherapy (#Brachytherapy)
Episode 2 — Cervical Cancer & HDR #Brachytherapy Boost after EBRT
The #EMBRACEII trial (1,482 patients, 49 centers) confirms that MR-guided adaptive brachytherapy remains essential for locally advanced cervical cancer.

✅ 93% local control (3 years)
✅ 94% pelvic control
✅ 82% overall survival (5 years)
✅ Reduced severe late toxicity vs EMBRACE I
📢 Modern radiotherapy + chemotherapy + image-guided brachytherapy = new standard of care.
#InterventionalRadiotherapy #CervicalCancer #RadiationOncology #ESTRO2025 #WomenHealth #CancerCare #ThisIsBrachytherapy

[Hathal Haddad @Radiooncology]

🔰 New Series: Awareness of #Interventional_Radiotherapy (#Brachytherapy)
Episode 1 — Prostate HDR Brachytherapy for #ProstateCancer
🔬 Monotherapy → low/intermediate-risk PCa (EQD2: 116–128 Gy)
⚡ Boost + EBRT → intermediate/high-risk PCa

@AmericanBrachy1 -endorsed competency framework now published 👇
📖 https://t.co/CLxuncTjID

#Brachytherapy #ProstateCancer #RadiationOncology #ThisIsBrachytherapy #BrachytherapyAwarenessDay

[DrKamrava @KamravaMD]

HEROICC trial reported at ESTRO
Hypofx definitive cervix, Phase 2 RCT
Worse bowel toxicity for 15 fx seen
Wasn't expecting to see such a big diff in EPIC bowel function
@Sushilberiwal @emmacfields @MattHarkenrider @AnnKloppMD @AndrewFarach @lucascmendez

[Muhammad Ali @dr_alimuhammad]

Kidney SABR on the front cover of @TheLancetOncol. A well-deserved recognition for @_ShankarSiva for his work and efforts over the past 10+ years.

https://t.co/07jeA1lQMb

[Adam B. Weiner, MD @Adam_Weiner535]

🚨CAN-2409 + RT: not just delaying PSA failure, reducing residual tumor in the gland.🚨

@TheLancetOncol

👉Phase 3, double-blind RCT
🧑‍🤝‍🧑745 pts w/ int/high-risk localized #prostatecancer
⚖️EBRT + intraprostatic CAN-2409/valacyclovir vs placebo.

💉CAN-2409 is a replication-defective adenoviral HSV-tk gene therapy injected into the prostate.
💊Valacyclovir acts as the prodrug to drive local tumor-cell kill + immune priming

📉 DFS improved: HR 0.70; median NR vs 86.1 mo.

🔬 Key nuance: DFS included local failure by centrally reviewed positive prostate biopsy, protocol biopsy ~2 yrs post-EBRT.

🎯 At 22–26 mo: positive biopsies 20% vs 36%; pCR 80% vs 63%.

🛡️ No major toxicity penalty: grade ≥3 TEAEs 8% vs 7%; no treatment-related deaths.

🔑CAN-2409 may not just suppress biochemical recurrence, it may deepen local tumor eradication after RT.

@PCFnews @PCF_Science @urotoday @UrologyTimes

🔗https://t.co/GyvKotnfdK

[JAMA Oncology @JAMAOnc]

Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.

https://t.co/dWT4cR4GT9

[Tyler Seibert MD PhD @TylerSbrt]

@DrYukselUrun @HimanshuNagarMD @DrSpratticus @seanmmcbride @NehaVapiwala @CZamboglou @alison_tree @ASCO Yes! But for protons and prostate cancer, QoL gains were imagined. We (rad onc) try so hard to maximize RT precision (as we should!). But sometimes weak associations between dose and AEs cited so often we start to believe causality and precise predictions w/o proving it first.

[Tyler Seibert MD PhD @TylerSbrt]

@HimanshuNagarMD @DrSpratticus @seanmmcbride A perfect example of where beautiful dosimetric arguments do not pan out for patient benefit. Hence, we run trials.

And maybe we should reconsider dosimetry. I’m sure it matters! But we may be focusing on the wrong metrics. @NehaVapiwala @CZamboglou @alison_tree

[PDBrown @PDBrownOnc]

🚨🚨 ASCO 2026 Final Results Randomized trial resected brain met Brachytherapy vs Post-Op SRS🚨
- Incredible Surg Bed Control with Brachy (↑↑OS as well)
- Surg bed recurrence 12% SRS vs 1% GammaTile

[Daniel E Spratt @DrSpratticus]

@jjnaylor02 @TylerSbrt @VedangMurthy @piet_ost @DrAndrewLoblaw With that said, people thought neoadj ADT was critical before RT and it took decades to finally prove it likely adds almost no benefit and it really is the adjuvant component.

When outcomes already so good every percent matters…hard to prove each last percent.

[URONCOR @URONCOR]

¡Otro gran trabajo en #ESTRO2026! Compartimos los resultados a largo plazo de la braquiterapia HDR boost en cáncer de próstata (TC based vs TRUS). Datos robustos con más de 10 años de seguimiento medio que avalan un excelente control y supervivencia de los pacientes.

[Joel Poder @JPoderMedPhys]

Fantastic long term data for HDR boost. Very interesting to see lower side effect profile for TRUS based over CT based planning. More confidence in contouring or greater certainty in needle positioning at time of treatment? @agomeziturriaga @KamravaMD

[NonsparseOncologist @5_utr]

❗️ AREST

pT1-2N0 SCC oral cavity SCC w/intermediate risk factor(s) -> adjuvant RT vs observation

3-year LRFS HR 0.52 (0.30-0.91) in favor of adjuvant RT

Wow #ASCO26

[American Brachy @AmericanBrachy]

Join us at #ABSBrachy26 for the #judithstitt Plenary as Bryce Thomsen presents a Phase II randomized, blinded trial comparing AI‑assisted & manual contouring by new learners in ultrasound‑based #prostate HDR #brachy, with @AndrewFarach providing the discussant perspective.

[Priyamvada Maitre @docpriyamvada]

🤩 Finally OUT in @JCO_ASCO!

BART RCT from 🇮🇳 largest ph3 for adjuvant RT in high risk MIBC post cystectomy

A decade of persistence from @VedangMurthy ☺️
@RadOncTMC @TataMemorial @ACTREC_TMC
@PaulSargos
@Xristodouleas

https://t.co/B8iTgImLHr

[Muhammad Ali @dr_alimuhammad]

@DavidSherMD @_ShankarSiva @neildwallaceie @PeterMacRadOnc @ClevelandClinic @RoswellPark @videtig @Single_Fx_Singh @HardcastleNick @HardenSusan @MdStephans @marcfarrugia @DrewMoghanaki @JeffBradleyMD @piet_ost @Mat_Guc At Peter Mac, we use 30/1 for lung primary and metastatic from most radioresistant histologies, and 28/1 for metastatic disease. Other centres may be 34/1

[Neil Desai @ndesai2005]

@HimanshuNagarMD @TylerSbrt @piet_ost @DrStish Think remains possible. ASTRO 2025 PCSVI presentation by Dr Niazi showed lower late GI with HDR/EBRT vs MHRT - first time BT boost less AEs. I believe PRIME @VedangMurthy so far equal for SBRT and fractionated RT (although less with weekly SBRT). Curious to compare as mature

[David Kirsch, MD, PhD @DKirschMDPhD]

Congratulations to Dr. Laura Dawson on receiving the honorary member award from ESTRO!
@ldawsonmd
@UofTDRO
@RadMedPM
@PMResearch_UHN
@pmcancercentre
@UHN

[Pierre Blanchard, MD @PBlanchardMD]

@sri2912 @GETUG_Unicancer @TylerSbrt @VedangMurthy @piet_ost @NehaVapiwala @DrSpratticus @AlbertoBossial @_ShankarSiva @alongi_filippo @ChadTangMD @DrewMoghanaki Trial designed in 2012. Main reason.
At that time we had no result on hypofrac.

Besides we still as of today have limited evidence of hypofrac with whole pelvic RT.

[Pierre Blanchard, MD @PBlanchardMD]

Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging).

Twittorial below

Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)...

1/n